Myocardial ischaemia as a result of treatment with capecitabine;Myocardischemie als gevolg van behandeling met capecitabine

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 26, 2007, Pages 1469-1473

  Van Halteren, H K ^a   Liem, A H ^b   Planting, A S T ^c  

^a Afd Interne Geneeskunde   (Netherlands)

^b Afd Cardiologie   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; METOPROLOL; RALTITREXED;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE REPORT; COLORECTAL CARCINOMA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MALE; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA;

EID: 34447286854     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Cassidy J, Twelves C, Cutsem E van, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/ leucovorin. Ann Oncol. 2002;13:566-75.
2. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol. 2003;14:1735-43.
3. Cutsem E van, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004;90:1190-7.
4. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007;25:102-9.
5. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-9.
6. Cutsem E van, Twelves C, Cassidy J, Allman D, Bajetta E, Boyes M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastastic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097-106.
7. Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20: 3605-16.
8. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20: 3617-27.
9. Schnetzler B, Popova N, Collao Lamb C, Sappino AP. Coronary spasm induced by capecitabine. Ann Oncol. 2001;12:723-4.
10. Kuppens IE, Boot H, Beijnen JH, Schellens JHM, Labadie J. Capecitabine induces severe angina-like chest-pain. Ann Intern Med. 2004; 140:494-5.
11. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol. 2002;13:797-801.
12. Sestito A, Sgueglia GA, Pozzo C, Cassano AB, Barone C, Crea F, et al. Coronary artery spasm induced by capecitabine. J Cardiovasc Med (Hagerstown). 2006;7:136-8.
13. Cardinale D, Colombo A, Colombo N. Acute coronary syndrome induced by oral capecitabine. Can J Cardiol. 2006;22:251-3.
14. Rizvi AA, Schauer P, Owlia D, Kallal JE. Capecitabine-induced coronary vasospasm - a case report. Angiology. 2004;55:93-7.
15. Petrovic D. Effect of CMF-chemotherapy on blood coagulation in patients with breast cancer. Arch Oncol. 2002;10:61-6.
16. Pectasides D, Tsavdaridis D, Aggouridaki C, Tsavdaridou V, Visvikis A, Tsatalas K, et al. Effects on blood coagulation of adjuvant CNF (cyclophosphamide, novantrone, 5-fluorouracil) chemotherapy in stage II breast cancer patients. Anticancer Res. 1999;19:3521-6.
17. Boyle JJ, Wilson B, Bicknell R, Harrower S, Weissberg PL, Fan TP. Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J Pathol. 2000;192:234-42.
18. Ignatescu MC, Gharehbaghi-Schnell E, Hassan A, Rezaie-Majd S, Korschineck I, Schleef RR, et al. Expression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary atherosclerotic plaques. In vivo correlation of lesional microvessel density and constrictive vascular remodeling. Arterioscler Thromb Vasc Biol. 1999;19:2340-7.